Shares of Progenity (NASDAQ: PROG) were up more than 24% on Friday. The biotech company is developing a test called Preecludia that rules out preeclampsia, a pregnancy-related blood pressure disorder, while also specializing in gastrointestinal drugs and oral biotherapies. The stock has been a favorite of retail investors looking for a short squeeze.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting